Ignite Creation Date:
2025-12-24 @ 2:30 PM
Ignite Modification Date:
2026-01-01 @ 4:25 PM
Study NCT ID:
NCT07053059
Status:
RECRUITING
Last Update Posted:
2025-09-05
First Post:
2025-06-30
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL)
Sponsor:
M.D. Anderson Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-08-26
Start Date Type:
ACTUAL
Primary Completion Date:
2028-05-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2030-05-31
Completion Date Type:
ESTIMATED
First Submit Date:
2025-06-30
First Submit QC Date:
None
Study First Post Date:
2025-07-08
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-08-28
Last Update Post Date:
2025-09-05
Last Update Post Date Type:
ESTIMATED